OXINUS TABLETS

Dosage

Children: Refer to the specific drug's prescribing information for paediatric dosing.

Adults: Refer to the specific drug's prescribing information for adult dosing.

Mechanism of action

The mechanism of action varies depending on the specific drug combined with hydrochloride. Generally, hydrochloride salts enhance the solubility of the active ingredient, allowing for better absorption in the gastrointestinal tract. This can lead to improved therapeutic effects.

Pharmacodynamics

Pharmacodynamics is drug-specific and dependent on the active ingredient in the hydrochloride form. Typically, hydrochloride salts do not alter the pharmacodynamics of the parent drug but can enhance efficacy by improving bioavailability.

Pharmacokinetics

Pharmacokinetic properties such as absorption, distribution, metabolism, and excretion vary with each specific hydrochloride medication. Generally, hydrochloride salts are designed to be absorbed quickly from the gastrointestinal tract, allowing for rapid onset of action.

Contra-indications

• Hypersensitivity to hydrochloride or any component of the formulation
• Severe renal impairment
• Anuria

Adverse effects

• Dizziness
• Headache
• Nausea
• Vomiting
• Electrolyte imbalances
• Hypotension
• Dehydration

Interactions

• Increased risk of hypotension when used with other antihypertensives
• May enhance the effects of diuretics and other drugs that affect electrolyte balance
• Potential interaction with NSAIDs, which may reduce renal function

Precautions

• Monitor renal function regularly, especially in patients with pre-existing renal conditions
• Use with caution in patients with liver impairment
• Elderly patients may be more sensitive to the effects

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised as it is not known whether hydrochloride is excreted in human milk. Evaluate the risks and benefits before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Oral solution
• Injectable forms

Indications

• Overactive bladder syndrome
• Urinary incontinence
• Urinary urgency
• Neurogenic bladder

Dosage

Children: For children aged 5 to 11 years, the recommended dose is 5 mg taken orally two to three

Adults: The usual adult dose of oxybutynin is 5 mg taken orally two to three times daily. The maximum recommended dose is 20 mg per day.

Mechanism of action

Oxybutynin acts to relax the bladder by inhibiting the muscarinic action of acetylcholine on smooth muscle, particularly by competitively inhibiting the postganglionic type 1, 2, and 3 muscarinic receptors. This inhibition leads to increased bladder capacity, decreased urinary urgency and frequency, and delays the initial desire to void.

Pharmacodynamics

Oxybutynin exerts antispasmodic actions on the bladder, relieving symptoms associated with overactive bladder. These effects are a result of the drug's ability to inhibit muscarinic receptors, which mitigates urinary urgency and frequency. However, it may also cause anticholinergic side effects like hallucinations, confusion, agitation, and drowsiness. Monitoring for these symptoms is essential, and discontinuation of the drug should occur if angioedema is suspected.

Pharmacokinetics

Oxybutynin is well absorbed following oral administration, with peak plasma concentrations typically occurring within 1 to 2 hours. It undergoes extensive first-pass metabolism in the liver, primarily converting to its active metabolite, N-desethyloxybutynin. The elimination half-life is approximately 2 to 3 hours, and the drug is mainly excreted in the urine. The pharmacokinetics may be affected by age, liver function, and concomitant medications, necessitating potential dose adjustments.

Contra-indications

• Hypersensitivity to oxybutynin or any component of the formulation
• Urinary retention
• Severe ulcerative colitis
• Glaucoma
• Myasthenia gravis

Adverse effects

• Dry mouth
• Constipation
• Dizziness
• Nausea
• Somnolence
• Vision changes
• Angioedema
• Hallucinations
• Confusion
• Agitation

Interactions

• Anticholinergic drugs may enhance oxybutynin's effects and increase the risk of side effects
• CYP3A4 inhibitors may increase oxybutynin levels and effects
• CYP3A4 inducers may decrease oxybutynin levels and effects

Precautions

• Use with caution in patients with liver or kidney impairment
• Monitor for anticholinergic effects, especially in elderly patients
• Caution is advised when performing tasks that require alertness until response to the drug is known

Pregnancy

Oxybutynin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult relevant medical guidelines.

Breast-feeding

Oxybutynin is excreted in breast milk. Caution should be exercised when administered to nursing women.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Extended-release tablets
• Transdermal patches
• Syrup

Mechanism of action

Oxybutynin acts to relax the bladder by inhibiting the muscarinic action of acetylcholine on smooth muscle, and not skeletal muscle. The active of oxybutynin is metabolite is N-desethyloxybutynin. It competitively inhibits the postganglionic type 1, 2 and 3 muscarinic receptors. The above actions lead to increased urine capacity in the bladder, decreasing urinary urgency and frequency. In addition, oxybutynin delays the initial desire to void. RESULTS OF CYSTOMETRIC STUDIES SHOWED THAT THE DRUG INCR BLADDER CAPACITY @ ONSET OF FIRST CONTRACTION & FIRST DESIRE TO VOID, AS WELL AS @ END OF CYSTOMETRY. /CHLORIDE/

Pharmacodynamics

Oxybutynin exerts antispasmodic actions on the bladder, relieving the uncomfortable symptoms of overactive bladder, including urinary urgency and frequency. These actions occur through the inhibition of muscarinic receptors. **A note on angioedema and anticholinergic effects** Symptoms of angioedema may occur with oxybutynin therapy. If angioedema is suspected, discontinue oxybutynin immediately and provide appropriate medical treatment. In addition, anticholinergic effects may occur with the administration of this drug. Some symptoms may include hallucinations, confusion, agitation, and drowsiness. It is advisable to avoid operating heavy machinery before the response to oxybutynin has been monitored. Dose adjustments may be required.